Movement Alert|Veradermics, Inc. Falls 12.98% in Regular Trading, Q3 Loss Widens as Investors Assess Clinical Updates and Recent Target Hikes

Market Focus11-12

On November 12, Veradermics, Inc. fell 12.98% in Regular Trading to $135.7 per share, with turnover of $104.0 million.

The move followed continued market reassessment of the company’s recently reported third-quarter results and follow-up clinical disclosures, despite a narrower-than-expected loss and several recent analyst price-target increases.

Veradermics, Inc. reported a third-quarter net loss of $21.0 million, wider than the $20.1 million loss a year earlier but better than the $26.5 million loss expected by analysts, with no revenue reported. Cash, cash equivalents and marketable securities stood at $798.4 million at September 30, which management said should fund operations into 2030. The company also said VDPHL01 met co-primary efficacy endpoints in two registration-directed male pattern hair loss studies, while initial topline data from the female registration-directed trial remain expected in the first half of 2027. Recent target-price increases included $185 from $150, $175 from $160, and $204 from $170, but those updates did not prevent near-term selling pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment